Embecta (NASDAQ:EMBC) Updates FY 2026 Earnings Guidance

Embecta (NASDAQ:EMBC) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.550-1.75 for the period, compared to the consensus estimate of 2.820. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.1 billion.

Embecta Price Performance

NASDAQ EMBC traded down $0.06 during trading on Wednesday, hitting $3.85. The company’s stock had a trading volume of 2,458,163 shares, compared to its average volume of 991,520. The company has a market cap of $227.70 million, a PE ratio of 1.63 and a beta of 1.09. The business’s 50 day simple moving average is $9.12 and its 200-day simple moving average is $11.20. Embecta has a fifty-two week low of $3.82 and a fifty-two week high of $15.55.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.15). The business had revenue of $221.80 million during the quarter, compared to analyst estimates of $235.67 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.Embecta’s revenue was down 14.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.70 EPS. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. Analysts expect that Embecta will post 2.82 EPS for the current fiscal year.

Embecta Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Thursday, May 28th will be paid a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Thursday, May 28th. Embecta’s dividend payout ratio (DPR) is presently 25.32%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Wall Street Zen upgraded Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. BTIG Research cut Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday. Mizuho reduced their price target on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Four research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $15.00.

Key Headlines Impacting Embecta

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Board declared a quarterly cash dividend of $0.01 per share (payable June 15, 2026; record date May 28). This provides a small income signal to holders. embecta Announces Quarterly Cash Dividend
• Neutral Sentiment: Quarterly earnings call/transcript and company materials are available for detail — useful for investors who want to assess management commentary on demand trends, margin drivers and cost actions. Embecta Q2 2026 Earnings Transcript
• Negative Sentiment: Q2 results missed across the board: EPS $0.27 vs. $0.42 expected, revenue $221.8M vs. $235.7M expected, and revenue down 14.4% y/y — evidence of demand weakness that pressures near‑term profitability. View Press Release
• Negative Sentiment: FY‑2026 guidance was lowered to $1.55–1.75 EPS and revenue guidance came in below Street expectations (~$1.0B vs. ~$1.1B consensus), widening the gap with analyst models and increasing downside risk to estimates and the stock. View Slide Deck
• Negative Sentiment: Johnson Fistel announced an investigation into potential claims on behalf of Embecta investors against executives — this raises litigation risk/uncertainty and can amplify selling pressure. Johnson Fistel Investigation Notice

Institutional Investors Weigh In On Embecta

Several institutional investors have recently modified their holdings of EMBC. Pacer Advisors Inc. boosted its position in shares of Embecta by 49.3% in the 4th quarter. Pacer Advisors Inc. now owns 16,526 shares of the company’s stock valued at $196,000 after purchasing an additional 5,460 shares during the period. State of Tennessee Department of Treasury grew its position in Embecta by 23.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 53,290 shares of the company’s stock valued at $633,000 after acquiring an additional 10,263 shares during the period. Mackenzie Financial Corp grew its position in Embecta by 34.0% during the fourth quarter. Mackenzie Financial Corp now owns 135,085 shares of the company’s stock valued at $1,627,000 after acquiring an additional 34,240 shares during the period. XTX Topco Ltd purchased a new stake in Embecta during the fourth quarter valued at about $234,000. Finally, VARCOV Co. acquired a new position in shares of Embecta during the fourth quarter worth about $179,000. 93.83% of the stock is owned by hedge funds and other institutional investors.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.